<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/31948E7C-3029-415A-9EF4-1718F6EAA791"><gtr:id>31948E7C-3029-415A-9EF4-1718F6EAA791</gtr:id><gtr:firstName>Maria</gtr:firstName><gtr:surname>Montoya</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FI%2F00002014"><gtr:id>FEE43EAD-8BFE-461C-8C7A-E8CD0BAC9237</gtr:id><gtr:title>Epitope characterization for rational vaccine design</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/I/00002014</gtr:grantReference><gtr:abstractText>Identification and characterization of B and T epitopes in a given pathogen is crucial to understand the basic mechanisms for immunological protection, as well as for the formulation of efficient subunit vaccines. Protective immunity is usually mediated by either B lymphocytes or CD8+ or CD4+ T lymphocytes or both. Recognition of T epitopes by lymphocytes from different species and individuals is restricted by the major histocompatibility complex (MHC) polymorphism ?swine leukocyte antigen (SLA) in the case of pigs-, which are responsible of foreign antigen presentation by antigen presenting cells. Therefore, identification of T and/or B cell epitopes able to induce an efficient response and those epitopes which are presented by the predominant alleles of MHC in a given population from the host species is of paramount importance when designing new vaccine strategies. Tens of thousands of protein variants have been characterized in viruses and bacteria. In the case of human and mice, there is an extensive literature on B and T cell epitopes from influenza virus but, at the present time, there is no data available on influenza virus epitopes recognized by the pig?s immune system. Therefore, identification and optimization of T cell epitopes recognized by pigs from swine influenza virus is the main objective in this project.
This work will be performed by immunizing Babraham inbred pigs with inactivated swine influenza virus H1N1 and characterizing overlapping synthetic peptides from conserved proteins in the virus which are recognized by specific subsets of cells from peripheral blood in those immunised pigs. Characterization of the specific subsets of cells involved in recognition of those antigenic peptides will be also analysed. Also, preliminary work to generate transfected cells expressing individual SLA will be undertaken. Finally, techniques to isolate exosomes in pigs will be set up to characterize viral antigens in those microparticles.</gtr:abstractText><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-09-15</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>498238</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/I/00002014</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>